MedTrace Logo

Retrovirus Epidemiology Donor Study I (REDS I)

NCT00005278 · Status: COMPLETED · Type: OBSERVATIONAL

Last updated 2016-04-15

No results posted yet for this study

Summary

To conduct a multicenter epidemiologic study of the human retroviruses HIV-1, HIV-2, HTLV-I, and HTLV-II in volunteer blood donors from areas of the United States that were reportedly at high and medium or low risk for HIV. Also, to determine the prevalence of retrovirus seropositivity in first time blood donors; and the rate of retrovirus seroconversion in repeat blood donors as a measure of incidence of infection; to ascertain risk factors for antibody-positive donors; to characterize the blood donor population by geographic location, age, sex, race/ethnicity, and donation history to permit analysis on prevalence, incidence, and risk factors; to identify recipients of retrovirus-positive blood units and conduct clinical and laboratory follow-up of these recipients; and to establish a blood specimen repository for long-term storage of specimens from study donors and recipients for future testing.

Conditions

  • Acquired Immunodeficiency Syndrome
  • Blood Donors
  • Blood Transfusion
  • HIV Infections
  • HIV-1
  • HIV-2
  • HTLV-I
  • HTLV-II
  • Retroviridae Infections

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    lead NIH

Principal Investigators

  • George Garratty · American Red Cross Blood Services

  • Martha Higgens · American Red Cross Blood Services

  • Edward Murphy · University of California at San Francisco

  • Catharie Nass · American Red Cross Blood Services

  • George Schreiber · Westat, Inc.

  • James Smith · Oklahoma Blood Institute

Eligibility

Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1989-07-31
Primary Completion
2007-10-31
Completion
2007-10-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00005278 on ClinicalTrials.gov